Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million, linked to the FDA approval of GENGLYCOS (pariglasgene brebacarvovec-opnr), a one-time gene therapy for glycogen storage disease type Ia. The company described the move as non-dilutive capital to advance its rare-disease pipeline toward profitability. The PRV can be redeemed for priority review of a different subsequent marketing application or transferred to another company, and the transaction is subject to customary closing conditions. Ultragenyx previously benefited from PRV proceeds, reinforcing the program’s role in financing late-stage and follow-on development. For investors and rare-disease developers, the deal highlights how FDA voucher monetization continues to affect capital planning and timeline execution in ultra-rare categories.